Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00446082
First received: March 9, 2007
Last updated: November 7, 2016
Last verified: November 2016